Recent reporting on Canada’s venture capital market has highlighted growing concerns around the country’s ability to fund and retain high-growth companies.
A recent report from the Business Development Bank of Canada (BDC) described Canada’s early-stage investment gap as an emerging “economic sovereignty issue,” noting that foreign investors now participate in the majority of late-stage Canadian venture financings. Much of the discussion has focused on venture capital availability. However, another challenge facing Canadian innovation companies is the structure and timing of non-dilutive government funding programs already available to support growth.
Canada has a broad ecosystem of innovation support mechanisms, including grants, tax credits, repayable contributions, and government-backed financing programs. These include SR&ED tax incentives, IRAP funding, regional development agency programs, and sector-specific initiatives designed to support R&D, technology adoption, commercialization, and scale-up activities.
In many cases, however, these programs operate on a reimbursement or cost-sharing basis, requiring companies to secure and commit matching funds before government support is provided. This creates a “chicken-and-egg” situation where businesses may qualify for funding in principle, but still lack the upfront capital required to access it.
Companies are generally required to incur eligible expenditures before receiving reimbursement, contribution payments, or tax credit refunds. This means businesses must first finance payroll, contractor costs, equipment purchases, prototyping activities, or commercialization expenses internally before government funding is received.
For early-stage and scaling companies, this can create a significant working capital challenge.
For example:
- SR&ED tax credits are received after a fiscal year-end filing and processing period;
- IRAP and regional development programs often reimburse costs after claims are submitted and approved;
- Many contribution agreements require companies to maintain matching funding or demonstrate sufficient liquidity throughout the project period.
As venture investment activity slows and fundraising timelines lengthen, this timing mismatch becomes increasingly important. A company may technically qualify for substantial government support, while still lacking the operational cash flow required to execute the project and bridge the reimbursement period.
This dynamic is particularly relevant for capital-intensive sectors such as advanced manufacturing, cleantech, life sciences, and hardware development, where project expenditures are often incurred months before reimbursement occurs.
In many ways, grants, tax credits, and public innovation financing programs are intended to help reduce investment risk for private capital by offsetting portions of R&D, commercialization, and scale-up costs. However, companies often still require private investment, debt financing, or sufficient internal cash reserves in order to access that support in the first place.
As a result, the discussion around Canada’s innovation economy may extend beyond whether sufficient funding programs exist. Canada already maintains a relatively robust ecosystem of grants, tax credits, and public innovation supports across many sectors. Increasingly, the challenge appears to involve whether companies have adequate access to growth capital and working capital financing to leverage those programs effectively.
In practice, innovation support alone may not fully address commercialization and scale-up challenges if companies do not also have the liquidity required to carry project costs between expenditure and reimbursement.
